§ 522.775 **Doxapram.**

(a) **Specifications.** Each milliliter of solution contains 20 milligrams (mg) doxapram hydrochloride.

(b) **Sponsor.** See Nos. 000010 and 015914 in §510.600(c) of this chapter.

(c) **Conditions of use—(1) Amount.** For intravenous use in dogs and cats at a dose of 2 1/2 to 5 mg per pound (lb) body weight in barbiturate anesthesia, 0.5 mg/lb in inhalation anesthesia, 0.25 mg/lb with chloral hydrate with or without magnesium sulfate; for subcutaneous, sublingual, or umbilical vein administration in neonate puppies at a dose rate of 1 to 5 mg; for subcutaneous or sublingual use in neonate kittens at 1 to 2 mg. Dosage may be repeated in 15 to 20 minutes if necessary.

(2) **Indications for use.** Administer to dogs, cats, and horses to stimulate respiration during and after general anesthesia; or to speed awakening and return of reflexes after anesthesia. Administer to neonate dogs and cats to initiate respiration following dystocia or caesarean section; or to stimulate respiration following dystocia or caesarean section.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.778 **Doxycycline hyclate.**

(a) **Specifications.** Doxycycline hyclate solution contains 8.5 percent doxycycline activity. A syringe of N-methyl-2-pyrrolidone and poly (DL-lactide) mixed with a syringe of doxycycline produces 0.5 milliliter of solution.

(b) **Sponsor.** See No. 000061 in §510.600(c) of this chapter.

(c) **Conditions of use—(1) Dogs—(i) Amount.** Apply subgingivally to periodontal pocket(s) of affected teeth.

(ii) **Indications for use.** For treatment and control of periodontal disease.

(iii) **Limitations.** Do not use in dogs less than 1-year old. Use of tetracyclines during tooth development has been associated with permanent discoloration of teeth. Do not use in pregnant bitches. Use in breeding dogs has not been evaluated. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.800 **Droperidol and fentanyl citrate injection.**

(a) **Specifications.** Droperidol and fentanyl citrate injection is a sterile solution containing 20 milligrams of droperidol and 0.4 milligram of fentanyl citrate per cubic centimeter.

(b) **Sponsor.** See No. 000061 in §510.600(c) of this chapter.

(c) **Conditions of use.** (1) It is used in dogs as an analgesic and tranquilizer and for general anesthesia.


1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter.
§ 522.810 Embutramide, chloroquine, and lidocaine solution.

(a) Specifications. Each milliliter (mL) of solution contains 135 milligrams (mg) embutramide; 45 mg chloroquine phosphate, U.S.P.; and 1.9 mg lidocaine, U.S.P.

(b) Sponsor. See No. 059130 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. One mL per 5 pounds of body weight.

(2) Indications for use. For euthanasia.

(3) Limitations. Not for use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[70 FR 36337, June 23, 2005]

§ 522.812 Enrofloxacin.

(a) Specifications. Each milliliter (mL) of solution contains:

(1) 22.7 milligrams (mg) enrofloxacin or

(2) 100 mg enrofloxacin.

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(c) Related tolerance. See §556.226 of this chapter.

(d) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

(e) Conditions of use—(1) Dogs. Use the product described in paragraph (a)(1) of this section as follows:

(i) Amount. 2.5 mg per kilogram (/kg) of body weight (1.13 mg per pound) as a single, intramuscular, initial dose followed by use of tablets twice daily for 2 to 3 days beyond cessation of clinical signs to a maximum of 10 days.

(ii) Indications for use. For the management of diseases associated with bacteria susceptible to enrofloxacin.

(2) Cattle. Use the product described in paragraph (a)(2) of this section as follows:

(i) Amount. Single-dose therapy: 7.5 to 12.5 mg/kg of body weight by subcutaneous injection. Multiple-day therapy: 2.5 to 5.0 mg/kg of body weight by subcutaneous injection. Treatment should be repeated at 24-hour intervals for 3 days. Additional treatments may be given on days 4 and 5 to animals that have shown clinical improvement but not total recovery.

(ii) Indications for use. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni (previously Haemophilus somnus) in beef and non-lactating dairy cattle.

(iii) Limitations. Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of enrofloxacin in this class of cattle may cause milk residues. A withdrawal period has not been established.